Figure 3. Solid Tumor Growth Is Inhibited by Systemic RI-TATp53C′ Peptide Administration.

(A) Delivery of RI-TATp53C′-biotin to subcutaneous TA3/St tumors after IP administration to immune competent A/J mice.

(B) Reduction of solid TA3/St tumor growth in immune competent mice as a result of systemic administration of RI-TATp53C′. TA3/St cells were injected subcutaneously into A/J mice and allowed to grow to an average size of approximately 100 mm³. Mice were then sorted into treatment groups that received eight daily injections of vehicle (open circle) (n = 17), 650 μg of mutant peptide (open diamond) (n = 7), or 650 μg of wild-type RI-TATp53C′ peptide (open triangle) (n = 11). Final mean tumor volumes were 573 mm³ for vehicle-treated mice, 550 mm³ for mice treated with mutant peptide, and 268 mm³ for the wild-type RI-TATp53C′ peptide group.